Compass is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its scientific focus is the relationship between angiogenesis, the immune system and tumor growth.
Context is advancing T-cell engager bispecific antibodies for solid tumors, including CTIM-76, a CLDN6 x CD3 engager, and CT-202, a Nectin-4 x CD3 engager.
CVRx is a commercial-stage medical device company focused on minimally invasive neuromodulation solutions for patients with cardiovascular disease. Its proprietary platform technology is Barostim.
Cyabra was formed to effect itsBusinesscombination and now serves as a publicly traded company. Its fully owned subsidiary, Legacy Cyabra, is an Israeli company formed on July 13, 2017 that works to uncover disinformation.
Cyngn is an autonomous vehicle technology company focused on industrial uses of autonomous vehicles.
Datacentrex describes itself as a diversified technology driven enterprise operating a digital assetMiningbusiness, with plans to move into digital asset infrastructure,Data Centeroperations andQuantum Computingadjacent technologies.
Digital Brands is a curated collection of lifestyle brands, including Bailey 44, DSTLD, Stateside, Sundry and Avo, sold through direct-to-consumer and wholesale distribution.
Elicio is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers. Its pipeline targets driver tumor mutations using common, well-characterized neoantigens.
On July 17, 2025, the company announced private placements of 44,414,189 shares of common stock and pre-funded warrants for up to 5,728,662 shares at USD 10.00 per share. Aggregate gross proceeds were approximately USD 501.0 million, including USD 28.0 million paid in Bitcoin, and …
The announcement came on the day of the topline readout from the Phase 3 LUCIA study of DURAVYU in wet age related macular degeneration. The study did not meet its primary endpoint of non-inferiority, though the company reported vision improvements. It met key secondary …